-
Something wrong with this record ?
c-Myb regulates tumorigenic potential of embryonal rhabdomyosarcoma cells
P. Kaspar, J. Prochazka, M. Efenberkova, A. Juhasz, V. Novosadova, R. Sedlacek,
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01 to 2019-12-31
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01 to 2019-12-31
ROAD: Directory of Open Access Scholarly Resources
from 2011
Springer Nature OA/Free Journals
from 2011-12-01
Springer Nature - nature.com Journals - Fully Open Access
from 2011-12-01
- MeSH
- Rhabdomyosarcoma, Embryonal genetics metabolism pathology MeSH
- Resting Phase, Cell Cycle * MeSH
- G1 Phase * MeSH
- Gene Knockdown Techniques MeSH
- Carcinogenesis genetics metabolism pathology MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Proto-Oncogene Proteins c-myb genetics metabolism MeSH
- Gene Expression Regulation, Neoplastic * MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Rhabdomyosarcomas (RMS) are a heterogeneous group of mesodermal tumors, the most common sub-types are embryonal (eRMS) and alveolar (aRMS) rhabdomyosarcoma. Immunohistochemical analysis revealed c-Myb expression in both eRMS and aRMS. c-Myb has been reported to be often associated with malignant human cancers. We therefore investigated the c-Myb role in RMS using cellular models of RMS. Specific suppression of c-Myb by a lentiviral vector expressing doxycycline (Dox)-inducible c-Myb shRNA inhibited proliferation, colony formation, and migration of the eRMS cell line (RD), but not of the aRMS cell line (RH30). Upon c-Myb knockdown in eRMS cells, cells accumulated in G0/G1 phase, the invasive behaviour of cells was repressed, and elevated levels of myosin heavy chain, marker of muscle differentiation, was detected. Next, we used an RD-based xenograft model to investigate the role of c-Myb in eRMS tumorigenesis in vivo. We found that Dox administration did not result in efficient suppression of c-Myb in growing tumors. However, when c-Myb-deficient RD cells were implanted into SCID mice, we observed inefficient tumor grafting and attenuation of tumor growth during the initial stages of tumor expansion. The presented study suggests that c-Myb could be a therapeutic target in embryonal rhabdomyosarcoma assuming that its expression is ablated.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028917
- 003
- CZ-PrNML
- 005
- 20210114155326.0
- 007
- ta
- 008
- 210105s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-019-42684-y $2 doi
- 035 __
- $a (PubMed)31004084
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kaspar, Petr $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, 14220, Czech Republic. petr.kaspar@img.cas.cz.
- 245 10
- $a c-Myb regulates tumorigenic potential of embryonal rhabdomyosarcoma cells / $c P. Kaspar, J. Prochazka, M. Efenberkova, A. Juhasz, V. Novosadova, R. Sedlacek,
- 520 9_
- $a Rhabdomyosarcomas (RMS) are a heterogeneous group of mesodermal tumors, the most common sub-types are embryonal (eRMS) and alveolar (aRMS) rhabdomyosarcoma. Immunohistochemical analysis revealed c-Myb expression in both eRMS and aRMS. c-Myb has been reported to be often associated with malignant human cancers. We therefore investigated the c-Myb role in RMS using cellular models of RMS. Specific suppression of c-Myb by a lentiviral vector expressing doxycycline (Dox)-inducible c-Myb shRNA inhibited proliferation, colony formation, and migration of the eRMS cell line (RD), but not of the aRMS cell line (RH30). Upon c-Myb knockdown in eRMS cells, cells accumulated in G0/G1 phase, the invasive behaviour of cells was repressed, and elevated levels of myosin heavy chain, marker of muscle differentiation, was detected. Next, we used an RD-based xenograft model to investigate the role of c-Myb in eRMS tumorigenesis in vivo. We found that Dox administration did not result in efficient suppression of c-Myb in growing tumors. However, when c-Myb-deficient RD cells were implanted into SCID mice, we observed inefficient tumor grafting and attenuation of tumor growth during the initial stages of tumor expansion. The presented study suggests that c-Myb could be a therapeutic target in embryonal rhabdomyosarcoma assuming that its expression is ablated.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a karcinogeneze $x genetika $x metabolismus $x patologie $7 D063646
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a G1 fáze $7 D016193
- 650 12
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a genový knockdown $7 D055785
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a protoonkogenní proteiny c-myb $x genetika $x metabolismus $7 D020598
- 650 12
- $a G0 fáze $7 D016192
- 650 _2
- $a embryonální rhabdomyosarkom $x genetika $x metabolismus $x patologie $7 D018233
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Prochazka, Jan $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, 14220, Czech Republic. Czech Centre for Phenogenomics Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, 14220, Czech Republic.
- 700 1_
- $a Efenberkova, Michaela $u Microscopy Centre - LM and EM, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, 14220, Czech Republic.
- 700 1_
- $a Juhasz, Attila $u Czech Centre for Phenogenomics Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, 14220, Czech Republic.
- 700 1_
- $a Novosadova, Vendula $u Czech Centre for Phenogenomics Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, 14220, Czech Republic.
- 700 1_
- $a Sedlacek, Radislav $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, 14220, Czech Republic. radislav.sedlacek@img.cas.cz. Czech Centre for Phenogenomics Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, 14220, Czech Republic. radislav.sedlacek@img.cas.cz.
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 9, č. 1 (2019), s. 6342
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31004084 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114155325 $b ABA008
- 999 __
- $a ok $b bmc $g 1609252 $s 1120097
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 9 $c 1 $d 6342 $e 20190419 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20210105